Immunic (IMUX) and The Competition Critical Survey
Immunic (NASDAQ: IMUX) is one of 578 public companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its rivals? We will compare Immunic to similar companies based on the strength of its valuation, analyst recommendations, profitability, institutional ownership, risk, dividends and earnings.
Institutional & Insider Ownership
45.6% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 67.9% of Immunic shares are held by insiders. Comparatively, 15.6% of shares of all “Pharmaceutical preparations” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
This table compares Immunic and its rivals top-line revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Immunic Competitors||$2.14 billion||$226.77 million||-427.84|
Immunic’s rivals have higher revenue and earnings than Immunic. Immunic is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Risk & Volatility
Immunic has a beta of 3.68, meaning that its stock price is 268% more volatile than the S&P 500. Comparatively, Immunic’s rivals have a beta of 1.20, meaning that their average stock price is 20% more volatile than the S&P 500.
This is a summary of current ratings and price targets for Immunic and its rivals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Immunic presently has a consensus price target of $40.00, suggesting a potential upside of 201.20%. As a group, “Pharmaceutical preparations” companies have a potential upside of 63.66%. Given Immunic’s stronger consensus rating and higher probable upside, analysts plainly believe Immunic is more favorable than its rivals.
This table compares Immunic and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Immunic beats its rivals on 8 of the 13 factors compared.
Immunic Company Profile
Immunic, Inc., a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies for treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. Its lead development program is IMU-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH, which is in phase II clinical development for treatment of ulcerative colitis and relapsing-remitting multiple sclerosis. The company is also developing IMU-935, an inverse agonist of RORyt; and IMU-856 for the restoration of the intestinal barrier function. Immunic, Inc. is headquartered in San Diego, California.
Receive News & Ratings for Immunic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunic and related companies with MarketBeat.com's FREE daily email newsletter.